Biotech · Private company · Raleigh, NC, US
Antixero
Track this companyFree. Adds Antixero to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards1
- AntiXero: An extended duration solution for cancer-associated dry mouth.Fiscal year 2025 · $406.5KNIH RePORTER 1R43DE034316-01 · fetched Nov 12, 2026